MET and prostate cancer: The Phase I study NCT02207504 focused on the maximum tolerated dose (MTD), associated toxicities, and pharmacokinetic profile of crizotinib, a c-MET/RON small molecule inhibitor alone and in combination with standard dosing of enzalutamide in castration-resistant prostate cancer patients.